Search clinical trials for: SHR-7367

Total 1818 results

Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-7367 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Atridia Pty Ltd.

Completed

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Solid Tumors and Hematologic Malignancy

Australia
Sanjay Gandhi Postgraduate Institute of Medical...
Ram Manohar Lohia Institute of Medical Sciences, Lucknow

Terminated

Re-treatment of HCV Following DAA Failure

Chronic Hepatitis C

India
Shionogi

Completed

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Obesity

United States
HiberCell, Inc.
Covance

Terminated

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Clear Cell Renal Cell Carcinoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Colo-rectal Cancer | Transitional Cell Carcinoma of the Bladder | Other Solid Tumors

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Esophageal Squamous Cell Carcinoma | Progression to PD-1 Antibody

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Breast Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.

Alzheimer's Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Asthma With Eosinophilic Phenotype

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Primary Hypercholesterolemia

China
Shionogi

Completed

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

Obesity

United States
Shionogi

Completed

Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects (OLE)

Obesity

United States
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Qian Chu
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma (CAPSTONE)

Sarcomatoid Carcinoma of Lung

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Alzheimer's Disease

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

Prevention of Graft Rejection After Organ Transplantation

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

T2DM

China
Atridia Pty Ltd.

Completed

Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

Australia
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Eosinophilic Granulomatosis With Polyangiitis

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Lung Cancer
Beijing Suncadia Pharmaceuticals Co., Ltd

Active, not recruiting

Safety and Tolerability of SHR-1918 in Healthy Subjects

Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Henan Cancer Hospital

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Advanced Malignant Tumors

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Advanced Solid Tumors

China
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer

ER Positive/HER2 Low Breast Cancer

China
ArQule, Inc. (a wholly owned subsidiary of Merck...

Completed

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Solid Tumor

United States, Italy
Guangdong Hengrui Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject

IgA Nephropathy

China
Beijing Suncadia Pharmaceuticals Co., Ltd

Active, not recruiting

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single-dose Injection of SHR-2004 in Healthy Subjects

Prevention of Arterial and Venous Thrombosis

China
University of California, Irvine

Completed

Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction

Hypertrichosis

United States
Panafina, Inc.

Recruiting

A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis

Acute Pancreatitis

United States
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian

Netherlands
Beijing GoBroad Hospital

Not yet recruiting

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Advanced Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Gynaecologic Oncology

Gynaecological Malignancies

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours

Advanced Solid Tumours
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-A1904 in Patients With Advanced Solid Cancer

Advanced Solid Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Active, not recruiting

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

Pharmacokinetic
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Beijing Suncadia Pharmaceuticals Co., Ltd

Active, not recruiting

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

Hyperlipidemic

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Trial of SHR-4849 in Advanced Solid Tumors

Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China

3

Subscribe